These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 15546735)

  • 1. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
    Leahy JJ; Golding BT; Griffin RJ; Hardcastle IR; Richardson C; Rigoreau L; Smith GC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6083-7. PubMed ID: 15546735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.
    Hardcastle IR; Cockcroft X; Curtin NJ; El-Murr MD; Leahy JJ; Stockley M; Golding BT; Rigoreau L; Richardson C; Smith GC; Griffin RJ
    J Med Chem; 2005 Dec; 48(24):7829-46. PubMed ID: 16302822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
    Griffin RJ; Fontana G; Golding BT; Guiard S; Hardcastle IR; Leahy JJ; Martin N; Richardson C; Rigoreau L; Stockley M; Smith GC
    J Med Chem; 2005 Jan; 48(2):569-85. PubMed ID: 15658870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives.
    Clapham KM; Rennison T; Jones G; Craven F; Bardos J; Golding BT; Griffin RJ; Haggerty K; Hardcastle IR; Thommes P; Ting A; Cano C
    Org Biomol Chem; 2012 Sep; 10(33):6747-57. PubMed ID: 22814419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
    Hollick JJ; Rigoreau LJ; Cano-Soumillac C; Cockcroft X; Curtin NJ; Frigerio M; Golding BT; Guiard S; Hardcastle IR; Hickson I; Hummersone MG; Menear KA; Martin NM; Matthews I; Newell DR; Ord R; Richardson CJ; Smith GC; Griffin RJ
    J Med Chem; 2007 Apr; 50(8):1958-72. PubMed ID: 17371003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Judicious application of allyl protecting groups for the synthesis of 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl triflate, a key precursor of DNA-dependent protein kinase inhibitors.
    Aristegui SR; El-Murr MD; Golding BT; Griffin RJ; Hardcastle IR
    Org Lett; 2006 Dec; 8(26):5927-9. PubMed ID: 17165896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.
    Cano C; Barbeau OR; Bailey C; Cockcroft XL; Curtin NJ; Duggan H; Frigerio M; Golding BT; Hardcastle IR; Hummersone MG; Knights C; Menear KA; Newell DR; Richardson CJ; Smith GC; Spittle B; Griffin RJ
    J Med Chem; 2010 Dec; 53(24):8498-507. PubMed ID: 21080722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.
    Clapham KM; Bardos J; Finlay MR; Golding BT; Griffen EJ; Griffin RJ; Hardcastle IR; Menear KA; Ting A; Turner P; Young GL; Cano C
    Bioorg Med Chem Lett; 2011 Feb; 21(3):966-70. PubMed ID: 21216595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK).
    Hollick JJ; Golding BT; Hardcastle IR; Martin N; Richardson C; Rigoreau LJ; Smith GC; Griffin RJ
    Bioorg Med Chem Lett; 2003 Sep; 13(18):3083-6. PubMed ID: 12941339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK).
    Desage-El Murr M; Cano C; Golding BT; Hardcastle IR; Hummersome M; Frigerio M; Curtin NJ; Menear K; Richardson C; Smith GC; Griffin RJ
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4885-90. PubMed ID: 18678488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.
    Mould E; Berry P; Jamieson D; Hill C; Cano C; Tan N; Elliott S; Durkacz B; Newell D; Willmore E
    Biochem Pharmacol; 2014 Mar; 88(1):58-65. PubMed ID: 24418411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization.
    Ismail IH; Mårtensson S; Moshinsky D; Rice A; Tang C; Howlett A; McMahon G; Hammarsten O
    Oncogene; 2004 Jan; 23(4):873-82. PubMed ID: 14661061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OK-1035, a selective inhibitor of DNA-dependent protein kinase.
    Take Y; Kumano M; Hamano Y; Fukatsu H; Teraoka H; Nishimura S; Okuyama A
    Biochem Biophys Res Commun; 1995 Oct; 215(1):41-7. PubMed ID: 7575620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK).
    Cano C; Golding BT; Haggerty K; Hardcastle IR; Peacock M; Griffin RJ
    Org Biomol Chem; 2010 Apr; 8(8):1922-8. PubMed ID: 20449499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase.
    Izzard RA; Jackson SP; Smith GC
    Cancer Res; 1999 Jun; 59(11):2581-6. PubMed ID: 10363977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, crystal structure determination, and biological properties of the DNA-dependent protein kinase (DNA-PK) inhibitor 3-cyano-6-hydrazonomethyl-5-(4-pyridyl)pyrid-[1H]-2-one (OK-1035).
    Stockley M; Clegg W; Fontana G; Golding BT; Martin N; Rigoreau LJ; Smith GC; Griffin RJ
    Bioorg Med Chem Lett; 2001 Nov; 11(21):2837-41. PubMed ID: 11597411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and characterization of an ATP-peptide conjugate inhibitor of protein kinase A.
    Hines AC; Cole PA
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2951-4. PubMed ID: 15125966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors.
    Kravchenko DV; Kuzovkova YA; Kysil VM; Tkachenko SE; Maliarchouk S; Okun IM; Balakin KV; Ivachtchenko AV
    J Med Chem; 2005 Jun; 48(11):3680-3. PubMed ID: 15916416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors.
    Payne SL; Rodriguez-Aristegui S; Bardos J; Cano C; Golding BT; Hardcastle IR; Peacock M; Parveen N; Griffin RJ
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3649-53. PubMed ID: 20472428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair.
    Veuger SJ; Curtin NJ; Smith GC; Durkacz BW
    Oncogene; 2004 Sep; 23(44):7322-9. PubMed ID: 15286704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.